HK18894A - Covalently-modified bacterial polysaccharides,stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers,and methods of preparing such polysaccharides and conjugates and of confirming covalency - Google Patents

Covalently-modified bacterial polysaccharides,stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers,and methods of preparing such polysaccharides and conjugates and of confirming covalency

Info

Publication number
HK18894A
HK18894A HK188/94A HK18894A HK18894A HK 18894 A HK18894 A HK 18894A HK 188/94 A HK188/94 A HK 188/94A HK 18894 A HK18894 A HK 18894A HK 18894 A HK18894 A HK 18894A
Authority
HK
Hong Kong
Prior art keywords
polysaccharides
conjugates
preparing
methods
covalently
Prior art date
Application number
HK188/94A
Other languages
English (en)
Inventor
Stephen Marburg
Peter J Kniskern
Richard L Tolman
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of HK18894A publication Critical patent/HK18894A/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK188/94A 1984-05-10 1994-03-03 Covalently-modified bacterial polysaccharides,stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers,and methods of preparing such polysaccharides and conjugates and of confirming covalency HK18894A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60873884A 1984-05-10 1984-05-10

Publications (1)

Publication Number Publication Date
HK18894A true HK18894A (en) 1994-03-11

Family

ID=24437774

Family Applications (1)

Application Number Title Priority Date Filing Date
HK188/94A HK18894A (en) 1984-05-10 1994-03-03 Covalently-modified bacterial polysaccharides,stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers,and methods of preparing such polysaccharides and conjugates and of confirming covalency

Country Status (19)

Country Link
US (1) US4695624A (fr)
EP (1) EP0161188B1 (fr)
JP (1) JPH0825899B2 (fr)
KR (1) KR910002553B1 (fr)
CN (1) CN1020733C (fr)
AT (1) ATE62255T1 (fr)
AU (1) AU589559B2 (fr)
CA (1) CA1259450A (fr)
CY (2) CY1765A (fr)
DE (1) DE3582356D1 (fr)
DK (2) DK171420B1 (fr)
ES (1) ES8700298A1 (fr)
GR (1) GR851120B (fr)
HK (1) HK18894A (fr)
IE (1) IE58088B1 (fr)
IL (1) IL75064A (fr)
NZ (1) NZ211953A (fr)
PT (1) PT80413B (fr)
ZA (1) ZA853505B (fr)

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8304304A (nl) * 1983-12-14 1985-07-01 Landbouw Hogeschool Werkwijze voor het winnen van een gelvormend polysaccharide, het gewonnen gelvormende polysaccharide, het met behulp van een dergelijk polysaccharide gewonnen gel alsmede werkwijze ter bereiding van synthetische oligo- en polysacchariden.
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4837003A (en) * 1984-09-13 1989-06-06 Mallinckrodt, Inc. Radiolabeled antibody fragments
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5202431A (en) * 1985-07-08 1993-04-13 Fidia, S.P.A. Partial esters of hyaluronic acid
US5283323A (en) * 1985-08-07 1994-02-01 The United States Of America As Represented By The Department Of Health And Human Services Method of producing immune response
DE3601136A1 (de) * 1986-01-16 1987-07-23 Max Planck Gesellschaft Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren
CA1331355C (fr) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentialisation
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
CA1303292C (fr) * 1986-11-06 1992-06-09 Julia G. Levy Couplage anhydre ameliore
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
US4994385A (en) * 1987-10-30 1991-02-19 Abbott Laboratories Heterobifunctional coupling agents
US5002883A (en) * 1987-10-30 1991-03-26 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5204098A (en) * 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US5010176A (en) * 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
US4963534A (en) * 1989-05-19 1990-10-16 Merck & Co., Inc. Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents
US5019502A (en) * 1989-06-12 1991-05-28 Merck & Company, Inc. Process for removing bacterial endotoxin from gram-negative polysaccharides
US5045456A (en) * 1989-06-12 1991-09-03 Merck & Co., Inc. Process for removing bacterial endotoxin from gram-negative polysaccharides
US5039610A (en) * 1989-06-12 1991-08-13 Merck & Co., Inc. Process for removing bacterial endotoxin from gram-negative polysaccharides
AU651949B2 (en) * 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
AU651319B2 (en) * 1989-07-27 1994-07-21 Univax Biologics Incorporated Lipid A analog/immunogenic carrier conjugates and the use thereof as vaccines
WO1991006319A1 (fr) * 1989-10-27 1991-05-16 Arch Development Corporation Procedes et compositions de promotion de l'immunopotentialisation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
KR0158436B1 (ko) * 1989-12-14 1998-12-01 피에르 오. 페론 개선된 수막염균성 폴리사카라이드 결합체 백신
CA2047073A1 (fr) * 1990-07-19 1992-01-20 William J. Leanza Vaccins coconjugues comportant une proteine immunogene, des peptides lies a vih et des fractions anioniques
CA2047031A1 (fr) * 1990-07-19 1992-01-20 Stephen Marburg Vaccins conjugues de peptide-polysaccharide-proteine
IL99077A0 (en) * 1990-08-13 1992-07-15 Merck & Co Inc New embodiments of the hiv principal neutralizing determinant and pharmaceutical compositions containing them
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2073511A1 (fr) * 1990-11-14 1992-05-29 Matthew R. Callstrom Produits de conjugaison entre un poly(vinylglucide) et des proteines dans le but de stabiliser les proteines
CA2059692C (fr) * 1991-01-28 2004-11-16 Peter J. Kniskern Vaccin conjugue de polysaccharide contre les pneumocoques
CA2059693C (fr) * 1991-01-28 2003-08-19 Peter J. Kniskern Antigenes polysaccharides de streptococcus pneumoniae
WO1992016232A1 (fr) * 1991-03-12 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Conjugues de polysaccharide-proteine
ES2154637T3 (es) * 1991-05-14 2001-04-16 Univ Connecticut Aportacion de genes dirigidos que codifican proteinas inmunogenicas.
CA2070961C (fr) * 1991-06-14 2004-12-07 Michael Chorev Reactifs radiomarques a base de maleimide, reagissant avec les thiols
US5370872A (en) * 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5314811A (en) * 1992-07-13 1994-05-24 Merck & Co., Inc. Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5463028A (en) 1992-04-03 1995-10-31 The Trustees Of Columbia University In The City Of New York Reagents for generating a polyclonal hydrolytic antibody response against cocaine and the monoclonal hydrolytic antibodies against cocaine derived through these reagents
US5470997A (en) * 1992-04-06 1995-11-28 Biosite Diagnostics Incorporated Amphetamine derivatives and protein and polypeptide amphetamine derivative conjugates and labels
US5331109A (en) * 1992-04-06 1994-07-19 Biosite Diagnostics Incorporated Phencyclidine derivatives and protein and polypeptide phencyclidine derivative conjugates and labels
EP0635019B1 (fr) * 1992-04-06 1999-05-26 Biosite Diagnostics Inc. Derives opiaces et etiquettes et conjugues de derives opiaces polypeptidiques et proteiques
US5274122A (en) * 1992-10-15 1993-12-28 Merck & Co., Inc. Acidic derivatives of homocysteine thiolactone
US5314822A (en) * 1992-10-15 1994-05-24 Merck & Co., Inc. Method of clonal growth of Streptococcus pneumoniae
US6037455A (en) * 1992-11-09 2000-03-14 Biosite Diagnostics Incorporated Propoxyphene derivatives and protein and polypeptide propoxyphene derivative conjugates and labels
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5866132A (en) * 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
US5780606A (en) * 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
DK0833662T4 (da) 1995-06-23 2011-02-28 Smithkline Beecham Biolog Vaccinepræparat omfattende et Haemophilus influenza B-polysaccharidkonjugatantigen adsorberet på aluminiumphosphat
US6410025B1 (en) 1996-02-14 2002-06-25 Merck & Co., Inc. Polysaccharide precipitation process
PT897427E (pt) * 1996-02-14 2005-01-31 Merck & Co Inc Processo de precipitacao de polissacarideos
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
US6267961B1 (en) 1996-11-22 2001-07-31 Baxter International Inc. Direct methods for molar-mass determination of fragments of Haemophilus influenzae type b capsular polysaccharides and vaccine preparation
KR100593466B1 (ko) * 1997-01-21 2007-04-25 파스퇴르 메리오 세룸 에 박신 다당류-펩타이드접합체
US6087328A (en) * 1997-04-24 2000-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
US20040087020A1 (en) * 1997-05-28 2004-05-06 Chiron S.P.A. Culture medium with yeast or soy bean extract as amino acid source and no protein complexes of animal origin
EP2199382A3 (fr) * 1997-05-28 2010-09-22 Novartis Vaccines and Diagnostics S.r.l. Milieu de culture avec extrait d'amidon ou de soja en tant que source d'acides aminés et dépourvu de complexes protéiques d'origine animale
AU748973B2 (en) * 1997-07-17 2002-06-13 Baxter Healthcare Sa Immunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide
US6224880B1 (en) 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
ES2245805T3 (es) * 1997-10-03 2006-01-16 Galenica Pharmaceuticals, Inc. Polisacaridos que forman iminas, preparacion de los mismos y el uso de los mismos como adyuvantes de inmunoestimulantes.
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
WO1999055715A2 (fr) 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Conjugues d'antigene et de polysaccharide
US20030224011A1 (en) * 2001-05-29 2003-12-04 Conley Anthony J Hepatitis c virus conjugates
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
ATE419005T1 (de) * 2001-12-11 2009-01-15 Merck & Co Inc Staphylococcus aureus exopolysaccharid und verfahren
EP1961427A3 (fr) 2002-08-02 2009-11-04 GlaxoSmithKline Biologicals S.A. Vaccin antineisseria comprenant une combinaison d'antigenes
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
US7927858B2 (en) 2002-11-01 2011-04-19 Glaxosmithkline Biologicals, S.A. Drying process
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2172213B1 (fr) 2003-01-30 2013-04-03 Novartis AG Vaccins injectables contre les multiples serogroupes du meningocoque
KR20050114225A (ko) * 2003-03-07 2005-12-05 머크 앤드 캄파니 인코포레이티드 인플루엔자 바이러스 백신
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
ES2346314T3 (es) 2003-10-02 2010-10-14 Glaxosmithkline Biolog Sa Antigenos de b. pertussis y uso de los mismos en vacunacion.
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
PL1961426T3 (pl) 2003-10-02 2012-03-30 Gsk Vaccines S R L Skojarzone szczepionki przeciwko zapaleniu opon mózgowo-rdzeniowych
US20050169941A1 (en) * 2004-01-29 2005-08-04 Andrew Lees Use of amino-oxy functional groups in the preparation of protein-polysaccharide conjugate vaccines
KR100843362B1 (ko) 2004-04-20 2008-07-02 덴드리틱 나노테크놀로지즈, 인크. 증폭성 및 내부 관능성이 증진된 수지상 중합체
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
SI1740217T1 (sl) 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
US7811577B2 (en) 2004-06-01 2010-10-12 Merck Sharp & Dohme Corp. Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
EP2325236A1 (fr) 2005-04-20 2011-05-25 Dendritic Nanotechnologies Inc. Polymères dendritiques avec fonctionnalité intérieure et amplification renforcées
KR20130122810A (ko) 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
SG163615A1 (en) * 2005-07-11 2010-08-30 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
CN101227920A (zh) * 2005-07-19 2008-07-23 陶氏环球技术公司 重组流感疫苗
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP3020411A1 (fr) 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccin
CN101024669B (zh) * 2006-02-17 2013-03-13 福州昌晖生物工程有限公司 一种可溶性的多糖-蛋白交联抗原的制备方法
ES2670231T3 (es) 2006-03-22 2018-05-29 Glaxosmithkline Biologicals S.A. Regímenes para inmunización con conjugados meningocócicos
AU2007260687B2 (en) * 2006-06-14 2013-12-12 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
US7491517B2 (en) * 2006-07-19 2009-02-17 Jeeri R Reddy Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135
PL2066344T3 (pl) 2006-09-07 2011-10-31 Glaxosmithkline Biologicals Sa Skojarzona szczepionka zawierająca inaktywowany wirus polio
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
BRPI0810778A2 (pt) 2007-05-02 2011-09-13 Glaxosmithkline Biolog Sa kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo
WO2009000825A2 (fr) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccin
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
JP5689064B2 (ja) 2008-10-27 2015-03-25 ノバルティス アーゲー 精製方法
CN109248313B (zh) 2009-04-14 2023-01-17 葛兰素史密丝克莱恩生物有限公司 用于免疫接种以抵御金黄色葡萄球菌的组合物
WO2010141312A2 (fr) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Protéines de fusion flagelline et conjugués comprenant des antigènes pneumocoques et leurs procédés d'utilisation
WO2011017101A2 (fr) 2009-07-27 2011-02-10 Fina Biosolutions, Llc Procédé de production de vaccins à protéine-carbohydrate à niveau réduit de carbohydrate libre
AU2010288240B2 (en) 2009-08-27 2014-03-27 Novartis Ag Hybrid polypeptides including meningococcal fHBP sequences
EP2475385A1 (fr) 2009-09-10 2012-07-18 Novartis AG Vaccins combinés contre les maladies des voies respiratoires
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
JP5960055B2 (ja) 2009-10-27 2016-08-02 ノバルティス アーゲー 改変髄膜炎菌ｆＨＢＰポリペプチド
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US9044517B2 (en) 2009-12-17 2015-06-02 Fina Biosolutions, Llc Activation of polysaccharides via the cyanylating agent, 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), in the preparation of polysaccharide/protein conjugate vaccines
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
CN102869378A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
DK2560738T3 (da) 2010-04-23 2019-08-26 Serum Inst India Ltd Simpel fremgangsmåde til samtidig fjernelse af flere urenheder fra dyrkningssupernatanter til ultralave niveauer
ES2744471T3 (es) 2010-09-04 2020-02-25 Glaxosmithkline Biologicals Sa Ensayos de anticuerpos bactericidas para evaluar la inmunogenia y la potencia de vacunas de sacárido capsular meningocócico
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012065034A1 (fr) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Vaccins à base de conjugués de peptide énolase, contre staphylococcus aureus
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
GB201106225D0 (en) 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
WO2013068949A1 (fr) 2011-11-07 2013-05-16 Novartis Ag Molécule porteuse comprenant un antigène spr0096 et un antigène spr2021
DK2788023T3 (en) 2011-12-06 2016-12-19 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2903650B1 (fr) 2012-10-02 2018-04-04 GlaxoSmithKline Biologicals SA Conjugués saccharidiques non linéaires
SG11201502599TA (en) 2012-10-12 2015-05-28 Glaxosmithkline Biolog Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
PL2925355T3 (pl) 2012-11-30 2018-06-29 Glaxosmithkline Biologicals S.A. Antygeny pseudomonas i połączenia antygenów
US10287330B2 (en) 2012-12-27 2019-05-14 Glaxosmithkline Biologicals S.A. Methods and compositions relating to CRM197
CN105188747A (zh) 2013-02-01 2015-12-23 葛兰素史密斯克莱生物公司 包含toll样受体激动剂的免疫组合物的皮内递送
SG11201506858SA (en) 2013-03-08 2015-09-29 Crucell Holland Bv Acellular pertussis vaccine
WO2015033251A2 (fr) 2013-09-08 2015-03-12 Pfizer Inc. Compositions utilisables contre neisseria meningitidis et procédés associés
CA2939416A1 (fr) * 2014-02-14 2015-08-20 Pfizer Inc. Conjugues de glycoproteine immunogenes
CA2940447C (fr) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Polypeptides fhbp meningococciques modifies
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (fr) 2014-12-19 2016-06-22 Novartis AG Purification de polysaccharides capsulaires de streptocoques
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
EP3269385A1 (fr) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composition de conjugués de polysaccharide-protéine pneumococcique
WO2017220753A1 (fr) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition de conjugué polysaccharide pneumococcique-protéine
CA3033364A1 (fr) 2016-09-02 2018-03-08 Sanofi Pasteur, Inc. Vaccin contre neisseria meningitidis
EP3530285B1 (fr) 2016-10-20 2023-08-09 KM Biologics Co., Ltd. PROCÉDÉ DE PRODUCTION D'UN VACCIN CONJUGÉ HIB UTILISANT DU PRP
DE POIDS MOLÉCULAIRE REDUIT
BE1025162B9 (fr) 2016-12-06 2019-01-07 Glaxosmithkline Biologicals Sa Procede de purification pour les polysaccharides capsulaires
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
BR112021000529A2 (pt) 2018-07-19 2021-04-06 Glaxosmithkline Biologicals S.A. Processos para preparar polissacarídeos secos
EP3607967A1 (fr) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Polypeptides modifiés du méningocoque fhbp
US20220054632A1 (en) 2018-12-12 2022-02-24 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
US20220118072A1 (en) 2019-02-11 2022-04-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3757217A1 (fr) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Procédés de purification de protéines
EP3777884A1 (fr) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Composition immunogène
CN115605222A (zh) 2019-09-27 2023-01-13 辉瑞公司（Us） 脑膜炎奈瑟氏菌组合物及其方法
EP3799884A1 (fr) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Compositions immunogènes
EP3900739A1 (fr) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Conjugués saccharides synthétiques de streptococcus pneumoniae à une protéine de membrane conservée
EP3919076A1 (fr) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccins synthétiques d'oligosaccharide contre le streptococcus pneumoniae avec des formulations d'adjuvant de microparticules
CN115803050A (zh) 2020-06-12 2023-03-14 葛兰素史克生物有限公司 使用纳米颗粒疫苗的细菌免疫
JP2023531242A (ja) 2020-06-25 2023-07-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変Ｅｘｏｔｏｘｉｎ Ａタンパク質
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
CA3201450A1 (fr) 2020-11-13 2022-05-19 Glaxosmithkline Biologicals Sa Transporteurs de proteine bacterienne et procedes de conjugaison
CA3211240A1 (fr) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Vaccin recombinant meningococcique b
WO2023111826A1 (fr) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Immunisation bactérienne utilisant des constructions de nanoparticules en épingle à cheveux qbêta
WO2023200704A1 (fr) 2022-04-11 2023-10-19 Sanofi Pasteur Inc. Conjugaison protéine-saccharide avec du cyanoborohydrure de sodium
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003792A (en) * 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US3856471A (en) * 1968-08-05 1974-12-24 Nasa Amino acid analysis
GB1316990A (en) * 1970-09-17 1973-05-16 Roche Products Ltd Imidazolyl derivatives
US4185090A (en) * 1972-02-02 1980-01-22 Abbott Laboratories Chemically modified endotoxin immunizing agent
CA1023287A (fr) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Procede de fixation d'une proteine sur un substrat
SE431758B (sv) * 1977-03-04 1984-02-27 Pharmacia Fine Chemicals Ab Som tioleringsreagens eller berarmatris for enzymer anvendbart derivat av en sh-grupphaltig polymer
US4275000A (en) * 1977-08-22 1981-06-23 National Research Development Corporation Peptide macromolecular complexes
US4286964A (en) * 1979-10-12 1981-09-01 Seed Brian S Polyfunctional epoxides and halohydrins used as bridging groups to bind aromatic amine group-containing alcohols and thiols to hydroxyl bearing substrates
US4415665A (en) * 1980-12-12 1983-11-15 Pharmacia Fine Chemicals Ab Method of covalently binding biologically active organic substances to polymeric substances
US4379843A (en) * 1981-01-26 1983-04-12 Peter Cashion Immobilization of polynucleotides and polypeptides with tritylated polysaccharides
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4451446A (en) * 1982-03-04 1984-05-29 Smithkline-Rit Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them
JPS58167519A (ja) * 1982-03-30 1983-10-03 Teijin Ltd 細胞毒性複合体及びその製造法
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
IE940698L (en) * 1984-04-05 1985-10-05 Univ Missouri Vaccine and serum for endotoxin associated disease and method of preparing same as well as to methods of immunization and treatment of such disease and to a detoxified endotoxin and bacterial mutant
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates

Also Published As

Publication number Publication date
NZ211953A (en) 1990-01-29
EP0161188A3 (en) 1987-07-22
KR850007982A (ko) 1985-12-11
PT80413A (en) 1985-06-01
DK205585D0 (da) 1985-05-09
ATE62255T1 (de) 1991-04-15
EP0161188A2 (fr) 1985-11-13
ES8700298A1 (es) 1986-10-16
JPS60248622A (ja) 1985-12-09
PT80413B (en) 1987-04-16
DK98595A (da) 1995-09-07
CA1259450A (fr) 1989-09-12
CY1765A (en) 1994-07-15
IE851134L (en) 1985-11-10
DE3582356D1 (de) 1991-05-08
GR851120B (fr) 1985-11-25
IL75064A (en) 1988-11-30
DK171420B1 (da) 1996-10-21
KR910002553B1 (ko) 1991-04-24
CN1020733C (zh) 1993-05-19
EP0161188B1 (fr) 1991-04-03
AU589559B2 (en) 1989-10-19
IE58088B1 (en) 1993-06-30
DK205585A (da) 1985-11-11
CY98041I2 (en) 2010-07-28
CN85104164A (zh) 1987-02-04
ES542919A0 (es) 1986-10-16
JPH0825899B2 (ja) 1996-03-13
DK171137B1 (da) 1996-06-24
ZA853505B (en) 1985-12-24
AU4221485A (en) 1985-11-14
IL75064A0 (en) 1985-09-29
US4695624A (en) 1987-09-22

Similar Documents

Publication Publication Date Title
IL75064A0 (en) Covalently-modified bacterial polysaccharides,stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers,and methods of preparing such polysaccharides and conjugates and of confirming covalency
GR853071B (fr)
DK49390A (da) Makrocykliske, bifunktionelle chelanter, komplekser deraf og deres antistofkonjugater
HU9303379D0 (en) Process for production of starpolymer-conjugates
AU1250483A (en) Conjugate of enzyme and antibody
NZ221065A (en) Conjugates of antibodies and toxins with sulphur-containing linking groups
EP0320942A3 (fr) Polysaccharides et composés macromoléculaires contenant ces polysaccharides
SG14094G (en) Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency.
SE8403929L (sv) Rekombinant-dna-molekyl, transformerade mikroorganismer och forfarande for framstellning av penicillin v-amidas
AU8177494A (en) Process for preparing clear sera which are stable over a long period

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20050505